44 results
8-K
EX-3.2
AMTI
Applied Molecular Transport Inc.
27 Dec 23
Completion of Acquisition or Disposition of Assets
3:49pm
on at the meeting; (c) rules and procedures for maintaining order at the meeting and the safety of those present; (d) limitations on attendance
DEFM14A
AMTI
Applied Molecular Transport Inc.
21 Nov 23
Proxy related to merger
9:16am
group study at a single clinical site in the U.S. The Phase I study evaluated the safety and pharmacokinetics of Trappsol® Cyclo™ along with markers … announced Top Line data showing a favorable safety and tolerability profile for Trappsol® Cyclo™ in this study.
Cyclo has also completed a Phase I/II
425
AMTI
Applied Molecular Transport Inc.
21 Sep 23
Business combination disclosure
5:12pm
leave, sick leave, occupational safety and health requirements (including any federal, state or local Laws and orders by Governmental Authorities … submitted Investigational New Drug (IND) applications to conduct clinical trials have been formally withdrawn without prejudice and not due to safety
8-K
EX-2.1
AMTI
Applied Molecular Transport Inc.
21 Sep 23
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement
5:10pm
service providers, whistleblower protection, family and medical leave, sick leave, occupational safety and health requirements (including any federal … formally withdrawn without prejudice and not due to safety reasons per CFR 312.38.
Section 3.25 Trade Laws.
(a) To the Knowledge of the Company
8-K
EX-99.1
pzd76bm1 71056fn1yv
22 Dec 22
Other Events
5:20pm
8-K
EX-99.1
akb4726f7ba6pw8gh
6 Jul 22
Other Events
8:01am
8-K
EX-99.1
clsutsjrd6a 1we4
18 May 22
Applied Molecular Transport Provides Strategy Update
8:18am
8-K
EX-99.1
6zfdcdxvu98929sae
25 Apr 22
Applied Molecular Transport Announces Positive Top-line Phase 2 Results from FILLMORE
8:01am
424B5
ut1oot
28 Mar 22
Prospectus supplement for primary offering
9:27pm
S-3
426bto61uv3bi
11 Mar 22
Shelf registration
5:03pm